CB21 Pharma, s.r.o.



Studentska 812/6, Bohunice, 625 00 Brno, Czech Republic,

Company ID: 075 63 094, <u>info@cb21pharma.com</u> tel: +420 776 291 231

Page 1 of 3

CERTIFICATE OF ANALYSIS

Product name: APOCAN 10g

Trade name: (–)-trans-Cannabidiol, PhG isolate

Manufacturer of API: CB21 Pharma s.r.o., Studentská 812/6, Bohunice,

625 00 Brno, Czech Republic, +420 776 291 231

Analytical specification: ASLL/KJ/CBD-PhG-03

Batch No. of the final product.: LL73112021 Batch No. of the used API: LL56092021 Mfg. Date of API: 09/2021

Mfg. Date of final product: 11/2021Quantity: $122 \times 10g$ Storage Conditions (if applicable): 15-25 °C Retest Date: 09/2023

Analytical specification number: ASLL/KJ/CBD-PhG-03

Parametr /Parameter	Limit	Výsledek / <i>Result</i>	Jednotka / <i>Unit</i>	Metoda / <i>Method</i>			
VLASTNOSTI / CHARACTERS							
Vzhled / Appearance	Téměř bílý až nažloutlý prášek / Whitish to yellowish powder	conforms	-	Visuálně / <i>Visual</i> (DAC/NRF 2020/2, C – 052)			
ZKOUŠKY TOTOŽNOSTI / <i>IDENTIFICATION</i>							
Zkouška totožnosti (IČ) / Identification IR spectrum	Shoduje se s IČ referenčním spektrem / Corresponds to the IR reference spectrum	conforms	-	Ph. Eur. 2.2.24 (FTIR) DAC/NRF 2020/2, C – 052			
STANOVENÍ OBSAHU / ASSAY							
Cannabidiol (CBD)	98.0 - 102.0	99.0	%	Ph. Eur. 2.2.29 (HPLC-DAD) DAC/NRF 2020/2, C – 052			
ZKOUŠKY NA ČISTOTU / TESTS							
Specifická optická otáčivost / Specific Rotation	-129.5 to -135.0	- 131.0	0	Ph. Eur. 2.2.7 DAC/NRF 2020/2, C – 052			
Síranový popel / Sulfated Ash	≤0.1	0.01	%	Ph. Eur. 2.4.14 DAC/NRF 2020/2, C – 052			



CB21 Pharma, s.r.o. Studentska 812/6, Bohunice, 625 00 Brno, Czech Republic,

Company ID: 075 63 094, info@cb21pharma.com tel: +420 776 291 231

Page 2 of 3

Parametr / Parameters	Limit	Výsledek / Result	Jednotka / Unit	Metoda / Method
Příbuzné látky / Related Substa	inces			
Cannabinol (CBN)	≤0.1	< 0.005	%	Ph. Eur. 2.2.29 (HPLC- MS/MS) Modified DAC/NRF 2020/2, C – 052
Δ9-tetrahydrocannabinol (Δ9-THC)	≤0.1	<0.005		
Δ8-tetrahydrocannabinol (Δ8-THC)	≤0.1	<0.005		
Další příbuzné látky / Other Re	elated Substances			
Cannabidivarin (CBDV)	≤0.5	0.0386	%	Ph. Eur. 2.2.29 (HPLC-MS/MS) Modified DAC/NRF 2020/2, C – 052
Cannabidiol-C4 (CBDB)	≤0.5	0.1338		
Nespecifikované nečistoty jednotlivě / Single unspecified impurities	≤0.1	RRT = 0.824 0.0010 RRT = 1.257 0.0005	%	
Nečistoty celkově / Total impurities	≤0.5	0.0023		
ZBYTKOVÁ ROZPOUŠT	ĚDLA / <i>RESIDUAL SO</i>	LVENTS		
Σ(Propan-2-ol, n-Heptane)	≤0.5	<0.025	%	Ph. Eur. 5.4 (2.2.32)
TĚŽKÉ KOVY / HEAVY M	METALS			
Cadmium (Cd)	<0.1	<0.1	ppm	ICP-MS
Lead (Pb)	<0.1	<0.1		
Arsen (As)	<0.1	< 0.03		
Mercury (Hg)	<0.01	<0.01		AAS-AMA
MIKROBIOLOGIE/MICR	OBIOLOGY		•	
Celkový počet aerobních mikroorganismů / Total aerobic microbial count (TAMC)	NMT 2,000	0	KTJ/CFU/g KTJ/CFU/g	Ph. Eur. 5.1.4; (2.6.12, 2.6.13)
Celkový počet plísní a kvasinek / Total combined yeasts/moulds count (TYMC)	NMT 200	0		
Escherichia coli	Nepřítomna / Absent/g	absent		



CB21 Pharma, s.r.o.

Studentska 812/6, Bohunice, 625 00 Brno, Czech Republic,

Company ID: 075 63 094, <u>info@cb21pharma.com</u> tel: +420 776 291 231

Page 3 of 3

Výsledek - rozhodnutí pro použití/Result - decision for use:

The tested batch conforms to the related specification of DAC/NRF 2020/2, C-052 and of the general chapters of European Pharmacopeia (Ph. Eur.). The mentioned batch was manufactured, analysed, handled and stored in accordance with Good Manufacturing Practise (GMP) in conformance with the above regulations and as outlined in the International Conference on Harmonized "ICH Q7 guideline on Good Manufacturing Practise for Active Pharmaceutical Ingredients".

Produkt vyhovuje specifikaci ASLL/KJ/CBD-PhG-03 a byl uvolněn k distribuci pro další zpracování /The product complies with the specification ASLL/KJ/CBD-PhG-03 and has been released for distribution for further processing.

07.01.2022

Approved by: Antonín Malík QM Director, QP

Release date: